Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results

被引:16
|
作者
Lambrecht, Marie [1 ,3 ]
Clementel, Enrico [2 ]
Sonke, Jan-Jacob [3 ]
Nestle, Ursula [4 ,5 ]
Adebahr, Sonja [5 ,6 ,7 ]
Guckenberger, Mathias [8 ]
Andratschke, Nicolaus [8 ]
Weber, Damien C. [8 ,9 ]
Verheij, Marcel [3 ]
Hurkmans, Coen W. [1 ]
机构
[1] Catharina Hosp, Dept Radiat Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[2] EORTC Headquarters, Dept Qual Assurance, Brussels, Belgium
[3] Netherland Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[4] Kliniken Maria Hilf GmbH Monchengladbach, Dept Radiat Oncol, Monchengladbach, Germany
[5] Univ Freiburg, Fac Med, Med Ctr, Dept Radiat Oncol, Freiburg, Germany
[6] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany
[7] German Canc Res Ctr, Heidelberg, Germany
[8] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland
[9] Paul Scherrer Inst, ETH Domain, Ctr Proton Therapy, Villigen, Switzerland
关键词
Benchmark; SBRT; Lung; Planning exercise; Clinical trial; RADIATION; ATLAS;
D O I
10.1016/j.radonc.2018.10.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report on the benchmark case (BC) study performed in the context of the European Organisation for Research and Treatment of Cancer prospective multicentre Lungtech trial of SBRT for patients with inoperable centrally located lung tumours. Methods and materials: Target volume and organs at risk (OARs) delineations first needed to be acceptable before the treatment plan was reviewed. Retrospectively, Dice similarity coefficients of the OARs and the target volumes were calculated and a set of gold standard contours adapted for each institution margins was applied on the accepted dose submissions to evaluate the influence of acceptable delineation variations on dosimetry. Results: Twenty-five institutions participated. Five BCs were accepted at the first attempt. Twenty institutions had to revise their delineation at least once and seven had to revise their planning once. The V-60 Gy dose coverage improved significantly (p = 0.05) between the first and final submissions from median (range) 94.8% (22.5-97.8) to 95.3% (70.5-99.3). The median Dice coefficient varied significantly between OARs: The lowest values were found for the brachial plexus 0.25 (0.01-0.54) and the highest for the spinal cord 0.89 (0.71-0.95). The mean PTV Dice coefficient was 0.82 (0.48-0.92). Applying the gold standard contours, only one institution remained compliant with the dose coverage criteria with V-60 Gy median (range) of 83.4% (54.2-93.9). Conclusions: Clinical guidelines and radiotherapy protocols are not a substitute for timely radiotherapy quality assurance procedures, which improve dose coverage significantly. Delineation remains the main source of BC rejection and plan review without first reviewing delineation may not be efficient. Our results show that delineation variations seem to have a larger influence on PTV coverage than variations in planning and irradiation techniques and thus suggest that dose tolerance criteria should preferably take into account the accuracy of delineation. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 50 条
  • [21] Quality assurance of radiotherapy in the ongoing EORTC 22042–26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case Reviews
    Mehtap Coskun
    William Straube
    Coen W Hurkmans
    Christos Melidis
    Patricia F de Haan
    Salvador Villà
    Sandra Collette
    Damien C Weber
    Radiation Oncology, 8
  • [22] Quality assurance of radiotherapy in the ongoing EORTC 22042-26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case Reviews
    Coskun, Mehtap
    Straube, William
    Hurkmans, Coen W.
    Melidis, Christos
    de Haan, Patricia F.
    Villa, Salvador
    Collette, Sandra
    Weber, Damien C.
    RADIATION ONCOLOGY, 2013, 8
  • [23] POSTOPERATIVE INTENSITY MODULATION RADIOTHERAPY (IMRT) FOR ENDOMETRIAL CANCER: RESULTS OF THE QUALITY ASSURANCE PROGRAM "DUMMY RUN" OF THE PHASE 2 RTCMIENDOMETRE FRENCH MULTICENTRE TRIAL
    Kreps, S.
    Barillot, I.
    Peignaux, K.
    Nickers, P.
    Leblanc-Onfroy, M.
    Williaume, D.
    Haie-Meder, C.
    Lerouge, D.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : XI - XI
  • [24] Protocol of a phase II study to evaluate the efficacy and safety of deep-inspiration breath-hold daily online adaptive radiotherapy for centrally located lung tumours (PUDDING study)
    Kishi, Noriko
    Yoneyama, Masahiro
    Inoo, Hiroyuki
    Inoue, Minoru
    Iramina, Hiraku
    Nakakura, Akiyoshi
    Ono, Tomohiro
    Hirashima, Hideaki
    Adachi, Takanori
    Matsushita, Norimasa
    Sasaki, Makoto
    Fujimoto, Takahiro
    Nakamura, Mitsuhiro
    Matsuo, Yukinori
    Mizowaki, Takashi
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [25] Protocol of a phase II study to evaluate the efficacy and safety of deep-inspiration breath-hold daily online adaptive radiotherapy for centrally located lung tumours (PUDDING study)
    Noriko Kishi
    Masahiro Yoneyama
    Hiroyuki Inoo
    Minoru Inoue
    Hiraku Iramina
    Akiyoshi Nakakura
    Tomohiro Ono
    Hideaki Hirashima
    Takanori Adachi
    Norimasa Matsushita
    Makoto Sasaki
    Takahiro Fujimoto
    Mitsuhiro Nakamura
    Yukinori Matsuo
    Takashi Mizowaki
    Radiation Oncology, 19
  • [26] POST OPERATIVE INTENSITY MODULATION RADIOTHERAPY (IMRT) FOR ENDOMETRIAL CANCER: RESULTS OF THE QUALITY ASSURANCE PROGRAM "DUMMY RUN" OF THE PHASE 2 RTCMIENDOMETRE FRENCH MULTICENTRE TRIAL
    Barillot, I.
    Peignaux, K.
    Castelain, B.
    Leblanc-Onfroy, M.
    Williaume, D.
    Haie-Meder, C.
    Lerouge, D.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S313 - S313
  • [27] Single agent gemcitabine in pretreated patients with non small cell lung cancer: results of an Argentinean multicentre phase II trial
    Van Kooten, M
    Traine, G
    Cinat, G
    Cazap, E
    Comba, AZ
    Vicente, H
    Sena, S
    Nievas, OR
    Orlando, M
    BRITISH JOURNAL OF CANCER, 1999, 81 (05) : 846 - 849
  • [28] Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Campbell, A. M.
    Cai, W. L.
    Burkhardt, D.
    Gettinger, S. N.
    Goldberg, S. B.
    Amodio, M.
    Kaech, S.
    Krishnaswamy, S.
    Decker, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S36 - S37
  • [29] A Phase II Trial of Stereotactic Body Radiotherapy (SBRT) in Patients with Stage IV Oncogene Driven Non-Small Cell Lung Cancer ( NSCLC)
    Keane, F. K.
    Yeap, B. Y.
    Lin, J.
    Piotrowska, Z.
    Khandekar, M. J.
    Willers, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S94 - S94
  • [30] Final results of a phase II trial of stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma (HCC) with Child-Pugh class A (CPC-A).
    Lasley, Foster D.
    Kwo, Paul
    Althouse, Sandra
    Perkins, Susan M.
    Maluccio, Mary A.
    Cardenes, Higinia Rosa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)